Proteomic profiling based classification of CLL provides prognostication for modern therapy and identifies novel therapeutic targets.

ABSTRACT: Protein expression for 384 total and post-translationally modified proteins was assessed in 871 CLL and MSBL patients and was integrated with clinical data to identify strategies for improving diagnostics and therapy, making this the largest CLL proteomics study to date. Proteomics identified six recurrent signatures that were highly prognostic of survival and time to first or second treatment at three levels: individual proteins, when grouped into 40 functionally related groups (PFGs), and systemically in signatures (SGs). A novel SG characterized by hairy cell leukemia like proteomics but poor therapy response was discovered. SG membership superseded other prognostic factors (Rai Staging, IGHV Status) and were prognostic for response to modern (BTK inhibition) and older CLL therapies. SG

SUBMITTER: Griffen TL 

PROVIDER: S-EPMC8931092 | biostudies-literature | 2022 Mar

REPOSITORIES: biostudies-literature